drugset
drugset / Trial / NCT07530224

JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis

NCT07530224 ↗

Phase 2 Not yet recruiting 35 enrolled Shixiu Wu
NaSingle-groupOpen-labelTreatment

Summary

Currently, the principal strategy for immune checkpoint inhibitors (ICI)-related dermatitis include systemic use of corticosteroids, which can impair the efficacy of preceding ICIs treatment. Janus kinase inhibitors (JAKi) could be the optimal option for ICI-related dermatitis, which can not only provide rapid relief for ICI-related dermatitis but also potentially enhance the anti-tumor efficacy of ICIs with minimal adverse events. This is an open-lable, phase II trial, aims to evaluate efficacy and safety of JAK inhibitors for solid malignant tumor patients with refractory ICI-related dermatitis.

Timeline

Start
2026-03-25
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tofacitinib Small molecule 5 mg Oral
Subject Upadacitinib Small molecule 15 mg Oral

Indications

No indication recorded.